Ap­peals court sides with Bris­tol My­ers Squibb in years-long bat­tle with in­vestors over Op­di­vo fail

Bris­tol My­ers Squibb’s years-long court bat­tle with in­vestors over a failed Op­di­vo study is com­ing to a close. Sec­ond Cir­cuit judges sided with the phar­ma gi­ant on Fri­day, af­firm­ing a fed­er­al court’s de­ci­sion to dis­miss a case sur­round­ing a lung can­cer tri­al for the block­buster PD-1 check­point in­hibitor.

Op­di­vo, al­so known as nivolum­ab, won its first ap­proval back in 2014 for ad­vanced melanoma, and has since tacked on a lengthy list of can­cer in­di­ca­tions. But this par­tic­u­lar case traces back to a dis­ap­point­ing 2016 read­out in non-small cell lung can­cer, which shed rough­ly $20 bil­lion off the com­pa­ny’s mar­ket cap in pre-mar­ket trad­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER